Interactive Brokers Nominates Lori Conkling to its Board of Directors
Interactive Brokers (Nasdaq: IBKR), an automated global electronic broker, announced the nomination of Lori Conkling as an independent director of the firm.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250307601860/en/
Lori Conkling (Photo: Business Wire)
Ms. Conkling will bring a wealth of knowledge to Interactive Brokers. As Head of TV & Film Licensing at Netflix, she oversees content acquisition and business development for their ad-free and ad-supported platforms. Before joining Netflix, she held leadership positions at Google, including Global Head of TV, Film and Sports for YouTube and YouTube TV.
“We are pleased to nominate Lori to the Board of Directors and look forward to leveraging her expertise to enhance our profile across the media landscape,” said Thomas Peterffy, Founder and Chairman of Interactive Brokers. “A successful senior executive with over 25 years of experience in the media space, Ms. Conkling will be a valuable resource helping to inform our media strategy and build brand awareness.”
Ms. Conkling has also served as Executive Vice President of Strategy and Business Development for Digital Enterprises at NBCUniversal, Executive Vice President of US and Canadian Distribution at A+E Networks, and Vice President of National Accounts for Disney and ESPN. She began her career with Accenture, where she analyzed and developed corporate strategies for publishing, film, and telecommunications companies.
Ms. Conkling holds an M.B.A. from Duke University's Fuqua School of Business and a B.S. in Business Administration from the University of Southern California. She sits on the Boards of Teach for America and the Fuqua School of Business's Board of Visitors.
The Best Informed Investors Choose Interactive Brokers
About Interactive Brokers Group, Inc.:
Interactive Brokers Group affiliates provide automated trade execution and custody of securities, commodities, foreign exchange, and forecast contracts around the clock on over 160 markets in numerous countries and currencies from a single unified platform to clients worldwide. We serve individual investors, hedge funds, proprietary trading groups, financial advisors and introducing brokers. Our four decades of focus on technology and automation have enabled us to equip our clients with a uniquely sophisticated platform to manage their investment portfolios. We strive to provide our clients with advantageous execution prices and trading, risk and portfolio management tools, research facilities and investment products, all at low or no cost, positioning them to achieve superior returns on investments. Interactive Brokers has consistently earned recognition as a top broker, garnering multiple awards and accolades from respected industry sources such as Barron's, Investopedia, Stockbrokers.com, and many others.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250307601860/en/
Contacts
Contacts for Interactive Brokers Group, Inc. Media: Katherine Ewert,
media@ibkr.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LEO Pharma Presents New Late-Breaking Delgocitinib Cream Data For the Third Consecutive Year at AAD 20258.3.2025 17:00:00 EET | Press release
LEO Pharma A/S, a global leader in medical dermatology, today presented late-breaking data showcasing responses in a subgroup of patients from the DELTA 1 and 2 trials at the 83rd American Academy of Dermatology (AAD) 2025 Annual Meeting.1 The presentation marks the third consecutive year that LEO Pharma has presented late-breaking data at AAD. Alongside this presentation, new systemic exposure data has also been shared for delgocitinib cream at the meeting.2 “The data unveiled today further contributes to LEO Pharma’s ever-growing body of scientific evidence for the treatment of moderate to severe CHE,” said Christophe Bourdon, Chief Executive Officer, LEO Pharma. “Our research and work in CHE is a testament to our ambition to maintain the broadest global product portfolio in dermatology, and I am proud we can share this latest analysis from our pivotal DELTA trials.” Delgocitinib cream is currently under investigation in the United States. Late-Breaking Post Hoc Data Analysis The sub
Incyte Announces Results of Phase 3 Clinical Trials Evaluating Ruxolitinib Cream 1.5% (Opzelura ® ) in Patients with Prurigo Nodularis (PN) at 2025 American Academy of Dermatology Annual Meeting8.3.2025 16:01:00 EET | Press release
Incyte (Nasdaq:INCY) today announced results from its pivotal Phase 3 TRuE-PN clinical trial program –TRuE-PN1 and TRuE-PN2 studies – evaluating the safety and efficacy of twice-daily ruxolitinib cream 1.5% (Opzelura®), a topical JAK1/2 inhibitor, in adult patients (≥18 years) with prurigo nodularis (PN). The positive TRuE-PN1 data were presented as a late-breaking oral presentation (Session: S028 – Late-Breaking Research: Session 1) today at the 2025 American Academy of Dermatology (AAD) Annual Meeting, being held March 7–11, 2025, in Orlando. The TRuE-PN1 study met its primary endpoint demonstrating that significantly more PN patients who applied ruxolitinib cream 1.5% versus vehicle control achieved a ≥4-point improvement from baseline in Worst-Itch Numeric Rating Scale (WI-NRS4) at Week 12 (44.6% vs 20.6%; P=0.0003). Significant itch improvements were observed with ruxolitinib cream 1.5% versus vehicle control at Day 7 (22.4% vs 8.0%; P=0.0064), with numerical improvements versus v
Proteintech Unveils Next-Gen 3D Epitope Mapping to Accelerate Life Science Research7.3.2025 21:16:00 EET | Press release
Proteintech, a global leader in antibodies and life science solutions, is excited to announce additional product characterization for primary antibody targets on its website (ptglab.com). The advanced validation data, 3D Epitope Mapping, is designed to enhance the efficiency and accuracy of antibody-related selection, empowering scientists with the data they need to advance their work, from basic research to the design of novel therapeutics. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250307777605/en/ On the Proteintech website (ptglab.com), researchers can explore antibody binding sites with the new interactive 3D epitope viewer. (Photo: Business Wire) The 3D Epitope Mapping is a state-of-the-art solution that utilizes a combination of experimental techniques, including peptide scanning and microbial display, aiming to precisely map the antibody binding site (epitope) on a target protein. This mapping is then visualized
I Squared Capital Appoints Philippe Lenoble and Bogdan Ciobotaru as Managing Directors7.3.2025 17:32:00 EET | Press release
I Squared Capital, a leading independent global infrastructure investment firm, today announced two senior appointments to its investment and asset management teams in London. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250306212222/en/ Philippe Lenoble, Managing Director, I Squared (Photo: Business Wire) Philippe Lenoble will join the investment team as Managing Director, reporting to Mohamed El Gazzar, Senior Partner. Bogdan Ciobotaru will join the asset management team as Managing Director reporting to Maxime Jacqz, Managing Director, who leads asset management in Europe. The demands for new and improved infrastructure requires investors to balance the increasing opportunities with the right resourcing to manage the increased scale and complexity. I Squared is committed to expanding its investment and asset management capabilities in a thoughtful and deliberate way to seize this opportunity and deliver value for its pa
Vertex Announces UK MHRA Approval of ALYFTREK ® (Deutivacaftor/Tezacaftor/Vanzacaftor), a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis7.3.2025 17:02:00 EET | Press release
Vertex Pharmaceuticals (Nasdaq: VRTX) announced today that the United Kingdom (UK) Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor),a once-daily next-in-class triple combination cystic fibrosis transmembrane conductance regulator (CFTR) modulator treatment for people living with cystic fibrosis (CF) ages 6 years and older who have at least one F508del mutation or another responsive mutation in the CFTR gene. “For more than 20 years we have been focused on discovering medicines that treat the underlying cause of the disease with the goal of helping people live longer and better lives. The approval of ALYFTREK, our fifth CFTR modulator regimen, represents another significant milestone in that journey for people with CF in the UK,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer at Vertex. “The deutivacaftor/tezacaftor/vanzacafto
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom